Sodium Iodide (131I) is a radiopharmaceutical containing the beta- and gamma-emitting radioisotope I-131. After absorption, the iodide is distributed through the extracellular fluid of the body and accumulates in the thyroid gland, thereby allowing the imaging of the thyroid.

The global Sodium Iodide (131I) for Therapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Sodium Iodide (131I) for Therapy Industry Forecast” looks at past sales and reviews total world Sodium Iodide (131I) for Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Sodium Iodide (131I) for Therapy sales for 2023 through 2029. With Sodium Iodide (131I) for Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sodium Iodide (131I) for Therapy industry.

This Insight Report provides a comprehensive analysis of the global Sodium Iodide (131I) for Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Sodium Iodide (131I) for Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sodium Iodide (131I) for Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sodium Iodide (131I) for Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sodium Iodide (131I) for Therapy.

In terms of product type, Capsule is the largest segment, with a share over 60%.

This report presents a comprehensive overview, market shares, and growth opportunities of Sodium Iodide (131I) for Therapy market by product type, application, key players and key regions and countries.

• Capsule
• Solution

• Hyperthyroidism Treatment
• Thyroid Cancer Treatment

This report also splits the market by region:

• United States
• Canada
• Mexico
• Brazil

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

• Germany
• France
• UK
• Italy
• Russia

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Curium Pharma
• HTA Co., Ltd.
• Jubilant Pharmova
• PDRadiopharma Inc.
• Yantai Dongcheng Pharmaceutical Group Co
• NTP Radioisotopes
• International Isotopes Inc
• ANSTO
• POLATOM（NCBJ）
• Isotope JSC (Rosatom)